Livzon Pharmaceutical Group (HK:1513) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Livzon Pharmaceutical Group Inc. has just received approval from the National Medical Products Administration for a new indication of their drug, Triptorelin Acetate Microspheres for Injection, specifically for the treatment of endometriosis. This marks a significant milestone for the company, expanding the potential market for their product and offering a new therapeutic option for individuals suffering from this condition.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
